TG Therapeutics Inc TGTX is trading lower Monday after the company announced worse-than-expected second-quarter financial results and H.C. Wainwright lowered its price target.
TG Therapeutics reported a quarterly earnings loss of 59 cents per share, which came in below the estimate for a loss of 50 cents. The company reported quarterly revenue of $1.54 million, up from $38,000 year over year.
H.C. Wainwright & Co. analyst Edward White maintained TG Therapeutics with a Buy rating and lowered the price target from $89 to $84.
The analyst said that the company gained access to customers as a result of COVID-19, which he expects could be a challenge moving into 2022.
Price Action: TG Therapeutics has traded as high as $56.74 and as low as $17.67 over a 52-week period.
At last check Monday, the stock was down 21.80% at $27.36.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
